SUMMARY Twelve patients with sinoatrial disease were assessed while on oral xamoterol (200 mg twice daily) and placebo by a double blind randomised, crossover trial that lasted four weeks.
Drug treatment of sinoatrial disease has not been established. Although sustained release isoprenaline (Saventrine) has been used in some patients it has not been the subject of a controlled trial. Other agents that have been proposed include amiodarone,' theophylline,2 hydralazine,3 and prenalterol.' But permanent cardiac pacing with adjuvant antiarrhythmic treatment remains the mainstay of treatment. Xamoterol (Corwin), (( ± ) -1 -(4 -hydroxyphenoxy) -3 -(2 -(4 -morpholine carbonamido) ethylamino)-propan-2-ol fumerate) is a ,B adrenoceptor partial agonist that is currently being evaluated for the treatment of mild to mod-. erate heart failure. Xamoterol acts as a fi, agonist at low levels of sympathetic tone and as a f blocker during period of excess sympathetic stimulation and therefore might provide a moderating influence on the heart rate of patients with sinoatrial disease.
Patients and methods
Twelve patients with sinoatrial disease were studied (table) . This diagnosis included slow atrial fibrillation in the absence of other heart disease, a condition which is predominantly a disorder of the atria and the inflow to the atrioventricular 
Results
All 12 patients completed the protocol with no new symptoms while on xamoterol. One patient had a stroke while on placebo. Xamoterol significantly shortened the modal R-R interval between the hours of midnight and 8 am (p < 0 01). This effect was less prominent at other times (fig 2) . The result was a reduction in the diurnal range of modal R-R intervals. Figure 3 compares the number of pauses > 1-74 s on placebo and xamoterol. Patients 3 and 9 did not have any prolonged pauses on either treatment. The pauses were abolished in three patients and substantially reduced in three others. Two patients had a slight increase in the number of pauses: the remaining two had a pronounced increase that was associated with symptomatic deterioration in one patient (case 4). In five patients the duration of the longest pause in the 24 hour period was considerably reduced (fig4). This value showed little change in four patients. In patient 4 the longest pause was increased from 4-48 to 6 50 s. In 10 patients the mean heart rate was increased by xamoterol ( fig 5) . In six this was associ- ated with some reduction in both the number and duration of pauses; five of these patients had the bradycardia-tachycardia syndrome. Six patients were started on long term xamoterol. Three, whose symptoms were still inadequately controlled, required permanent pacemakers. The three remaining patients were given no specific treatment.
Discussion
Six of 12 patients on short term xamoterol showed electrocardiographic improvement; one patient deteriorated. How reliable are these results? A crossover trial is commonly used for drug assessment, but we are not aware that it has been used to assess the treatment of sinoatrial disease. There are no earlier studies to assess either the reproducibility of the results or the predictive ability for long term successful treatment.
The pharmacology of xamoterol is important to the assessment of this trial. Experiments in dogs have demonstrated that increasing doses of xamoterol produce 43% of the maximum increase in heart rate brought about by isoprenaline but have no direct effects on resistance to blood flow in the perfused hind leg.7 So xamoterol has a highly selective fl1 agonist effect. The experiments also demonstrated that xamoterol competitively inhibits the effects of isoprenaline and noradrenaline on the heart rate. In doses that were 13 times higher, xamoterol also antagonised the vasodilator effect of isoprenaline on the perfused hind leg of a dog. Thus xamoterol has a partly selective P, antagonistic effect. Similar results have been demonstrated in normal volunteers, in whom xamoterol increased the heart rate at rest and reduced it during maximal exercise.8 9 Xamoterol increases the minimum heart rate and reduces the maximum heart rate in patients with chronic atrial fibrillation on digoxin treatment.'0 Xamoterol also has positive inotropic effects and these are being evaluated for the treatment of heart failure.'" Xamoterol warrants further assessment as a potential alternative to pacing in some patients with sinoatrial disease.
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